Walter Koroshetz

, MD

Director, National Institute of Neurological Disorders and Stroke

Dr. Walter J. Koroshetz  serves as Director of the National Institute of Neurological Disorders and Stroke (NINDS), which overseas much of the Alzheimer Related Dementia research at the National Institutes of Health (NIH). He joined NINDS in 2007 as Deputy Director and has held leadership roles in a number of NIH and NINDS programs including co-leading the NIH’s BRAIN Initiative, the NIH RECOVER Initiative in the study of Post Acute Sequelae of COVID-19, NIH Blueprint for Neuroscience, the NIH Post Acute Sequelae of Covid-19 Initiative, the Traumatic Brain Injury Center collaboration between the NIH intramural and the Uniformed Health Services University, the Helping to End Addiction Long Term (HEAL) Initiative. He co-leads a number of NIH Common Fund’s programs including the Undiagnosed Disease Network, the Acute to Chronic Pain Transition programs, Somatic Gene Editing program, and Somatic Cell Transformational ALS research program, and he was instrumental in founding the NIH Office of Emergency Care Research.

Before joining NINDS, Dr. Koroshetz served as Vice Chair of the neurology service and Director of stroke and neurointensive care services at Massachusetts General Hospital (MGH). He was a professor of Neurology at Harvard Medical School (HMS) and led neurology resident training at MGH between 1990 and 2007. Over that same period, he co-directed the HMS Neurobiology of Disease Course with Drs. Edward Kravitz and Robert H Brown.

A native of Brooklyn, N.Y., Dr. Koroshetz graduated from Georgetown University and received his medical degree from the University of Chicago. He trained in internal medicine at the University of Chicago and Massachusetts General Hospital. He then trained in Neurology and Neuroscience at MGH and Harvard Neurobiology focusing on how synaptic mechanisms might contribute to neuronal death including in Alzheimer’s disease. His early research in the lab and clinic focused on Huntington’s disease and with the team at MGH performed the first study of pre-symptomatic testing based on linkage analysis. A major focus of his clinical research career was the development of measures in patients that reflect the underlying biology of their conditions. This led to brain the development and validation of imaging techniques including Magnetic Resonance (MR) spectroscopy in Huntington’s disease; diffusion/perfusion MR and CT X-ray angiography and perfusion imaging in stroke. These stroke imaging tools are now commonplace in stroke care. Guided by these tools he pioneered acute clot removal for acute stroke patients with large artery occlusion, which is now practiced at Comprehensive stroke centers around the country. Through his work with the American Academy of Neurology, American Stroke Association and ACGME, he played a significant role in the revolution in acute stroke care in the U.S. and the growth of the neurointensive care field.

Read more

This Speaker's Sessions

Tuesday Oct. 17
1:30–2:15 PM ET
Watch Replay
Now Live!

Achieving Equity in Alzheimer's Disease

As Alzheimer’s therapies continue to make great progress, questions remain about how we can ensure equitable access to the right treatments, for the right patients, at the right time. What do we know--and not know--about the etiology of the disease in and the impact of new treatments on minoritized, and especially Black, populations?  Key Question: How do we achieve success with such low rates of racial and ancestral diversity in clinical trials?

View SessionWatch Replay